AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06207006 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eConquerFear-HK
Description: The key goals of the intervention are to: (i) teach strategies for controlling worry and excessive threat monitoring; (ii) modify underlying unhelpful MCQ beliefs about worry; (iii) develop appropriate monitoring and screening behaviours, (iv) encourage acceptance of the uncertainty brought about by a cancer diagnosis, and (v) clarify values and encourage engagement in values-based goal setting.
Study NCT06207006 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Cancer Care
Description: Basic Cancer Care serves as an active comparator and is not developed specifically to target fear of cancer recurrence through modifying participants' cognitive beliefs. Participants in this arm will receive 6 videos about relaxation, generic dietary and exercise knowledge.
Study NCT06369532 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: During the whole therapy period, active tDCS group will receive active tDCS after CBT. They also receive active home-based tDCS.
Study NCT06369532 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The sham tDCS group will receive sham tDCS after CBT. They also receive sham home-based tDCS.
Study NCT05532553 — intervention group
Intervention type: DEVICE
Intervention: Carotid Doppler U/S
Description: Measurement of carotid intima media thickness by carotid doppler ultrasound
Study NCT06482073 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT06510959 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Digital course
Description: The course aims to enhance participants' digital skills concerning the use of smartphones, specifically focusing on daily utility apps such as email apps, eGov apps, mobility apps, etc. The course is structured into the following ten 90-minute weekly lessons.
Study NCT05227898 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: Attune™
Description: People enrolled in the study use the app to complete ten informational sessions, each approximately 60-minute in length. The app also include guided exercises and other interactive opportunities.
Study NCT05227898 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device: Cerena™
Description: People enrolled in the study use the app to complete ten informational sessions, each approximately 60-minute in length. The app also include guided exercises and other interactive opportunities.
Study NCT05880810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor Dexcom G6 PRO
Description: Connected to a smart phone that transmits continuous glucose monitoring data in real time to Advanced Care at Home Command Center for monitoring.
Study NCT05491421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT002
Description: Participants will receive a single subcutaneous (SC) ZT002 dose of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under fasted conditions.~Participants will MAD Cohorts will receive a single subcutaneous (SC) ZT002 in following doses under fasting conditions-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings
Study NCT05491421 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive same volume as of the study drug of 0.03, 0.09, 0.18, or 0.3 mg/kg respectively, for SAD Cohorts 1 to 4 under the fasted condition.~Participants in MAD cohorts will receive same volume as study drug in the following cohorts under fasted condition-~* Cohort 1: 7.0mg, 10mg, 20mg;~* Cohort 2: 10 mg, 20mg, 40mg;~* Cohort 3: To be decided post safety review meetings
Study NCT06187025 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)
Description: Standardized clinical evaluations and screening of substance use using the World Health Organization Alcohol, Smoking and Drug Abuse Screening Test (ASSIST)
Study NCT06187025 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ecological Momentary Assessment (EMA)
Description: Daily EMA evaluations during 12 weeks
Study NCT05458856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin embonate 22.5 mg
Description: A prolonged release formulation of triptorelin pamoate 22.5 mg 6-month formulation in D, L-lactide-co-glycolide polymers for single subcutaneous injection on Day 1 and Day 169
Study NCT06469502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching Exercises
Description: Group 1 will be included in the program consisting of stretching exercises only. Patients will receive a 6-week rehabilitation program consisting of 18 sessions of stretching exercises (3 times a week) under the supervision of a physiotherapist.
Study NCT06469502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strengthening Exercises
Description: Group 2 will be included in the program consisting of strengthening exercises only. Patients will receive a 6-week rehabilitation program consisting of 18 sessions of strengthening exercises (3 times a week) under the supervision of a physiotherapist.
Study NCT05501535 — intervention group
Intervention type: DEVICE
Intervention: ND:YAG LASER
Description: The standard therapy for PCO is now Nd: YAG laser posterior capsulotomy, which has a success rate of more than 95%. The neodymium: yttrium-aluminum-garnet (Nd:YAG) laser, with a wavelength of 1064 nm, is a solid-state laser that may destroy ocular tissues by achieving optical breakdown with a brief, high-power pulse .Ionization or plasma production occurs in the ocular tissue as a result of optical breakdown. This plasma production subsequently generates acoustic and shock waves, which destroy tissue. Because of its cost-effectiveness, speed, and lack of invasiveness, it is the chosen treatment option in PCO
Study NCT05562349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clavulanic Acid Only Product
Description: Drug will be given in 250mg capsules
Study NCT05562349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule with no active medication - identical to drug capsule
Study NCT05552768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone level-driven placement
Description: The objective of this study will be to determine if implants placed according to the soft tissue-driving implant placement paradigm, i.e. 4 mm below the tissue margin will have different clinical performance as compared to the bone level-driven placement paradigm.
Study NCT05552768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biological width-driven placement guidelines
Description: Biological width-driven placement guidelines
Study NCT04745598 — intervention group
Intervention type: BEHAVIORAL
Intervention: Control group: Dental Model
Description: - Patients receive a demonstration of plaque control methods (modified Bass dental brushing technique and the use of the electric toothbrush) using a dental model.
Study NCT04745598 — intervention group
Intervention type: BEHAVIORAL
Intervention: Computer-assisted teaching format group
Description: - Patients receive a Powerpoint presentation containing:
Study NCT05999110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The intervention includes a personalized physical exercise program based on aerobic and strength training, with prior warm-up and post cool-down exercises. All participants also receive a nutritional advice session and a behavioral changes session.
Study NCT05491746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eye4
Description: Patients will see if the device helps them see better at distance and near and if it improves their contrast sensitivity.
Study NCT05491746 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is the patient's best corrected vision with or without glasses/contact lenses
Study NCT05566262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bodewell Calming Cream
Description: Bodewell is a non-prescription and contains 22 botanical ingredients in addition to colloidal oatmeal.
Study NCT04317326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lifestyle modifications group (Control)
Description: It will consist of a 1,000-calorie/day diet and to maintain proper sleep hygiene and habits (avoid supine decubitus position, maintain regular sleep habits and exercise, not take sedatives, stimulants, alcohol, tobacco or heavy meals within four hours before bedtime). Oxygen therapy can be prescribed by the treating team using standard criteria (awake PaO2 \<55 mmHg or room air oxygen saturation below 88% (Masa JF et al. J Clin Sleep Med. 2016 ;12:1379-88). The treatment period will be three months.
Study NCT04317326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Automatic NIV
Description: In addition to lifestyle modification and oxygen (if required), the ventilator will be adjusted to a range of predetermined parameters with the intelligent ventilation mode (pressure of intelligent support with guaranteed volume with automatic backup frequency) with the following adjustment: maximum pressure: 35 cmH2O; respiratory rate: automatic; maximum pressure support: 18 cm H2O; minimum pressure support: 4 cmH2O; maximum EPAP pressure: 15 cmH2O; minimum EPAP pressure: 4 cmH2O; and tidal volume (Vt) based on 8-10 ml/kg of predicted body weight, being able to be modified according to tolerance.The treatment period will be three months.
Study NCT04317326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPAP treatment group
Description: In-laboratory polysomnographic CPAP titration will be performed according to published guidelines for CPAP titration (SEPAR guideline or AASM guideline).In addition to lifestyle modification and oxygen (if require), a home titrated CPAP therapy will be initiated.The treatment period will be three years.
Study NCT04317326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NIV treatment groups
Description: In-laboratory polysomnographic NIV titration will be performed according to published guidelines In addition to lifestyle modification and oxygen (if required) home NIV therapy with fixed pressures will be started. The ventilator mode will be a bilevel pressure in S/T mode. The ventilator adjustment will be firstly performed in awake situation and then during sleep by means of a PSG. The treatment period will be three years.
Study NCT04745598 — intervention group
Intervention type: BEHAVIORAL
Intervention: Plaque-disclosing group
Description: - Patients place a few drops of a plaque-disclosing solution on the tongue and run the tongue over all the teeth and gums. With the aid of a hand mirror, patients can observe the stained plaque residue on their teeth
Study NCT04745598 — intervention group
Intervention type: BEHAVIORAL
Intervention: Intra-oral camera group
Description: - An ACTEON Soprocare® intraoral camera is used during the examination and explanation of oral hygiene strategies.
Study NCT05722626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP
Description: 2 ml of platelet rich plasma intraarticular injection twice in one week interval
Study NCT05722626 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: NaCl 0.9%
Study NCT05397509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive leaf tea
Description: 250 mL of Olive leaf tea and a high-glycemic breakfast
Study NCT05397509 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tea
Description: 250 mL of placebo tea and a high-glycemic breakfast
Study NCT05503485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Existential group treatment
Description: The existential group treatment follows a manualised structure focusing on aging-related challenges related to existential themes such as story of life, freedom, loneliness, and death. In order to support patients in finding new, productive ways of engaging in the existential process of aging literary texts, therapy practices and assignments between the sessions are used and each group will be accompanied by two therapists who facilitate the group climate, gently bring the group back on topic and help group members to see different ways of dealing with existential concerns related to aging.
Study NCT05503485 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive telephone calls
Description: The supportive caller will provide empathetic basic support, equivalent to the telephone support provided within the Swedish non-governmental organization Mind's Äldrelinjen. No psychotherapeutic techniques will be applied and there will be no interventions beyond the phone call itself.
Study NCT05093894 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1
Description: Microlyte will be cut into strips and placed on the subcutaneous space
Study NCT05862675 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RNA sequencing of blood samples
Description: Using omics techniques to detect blood samples from patients with acute lung injury and normal children, screen for marker genes related to immune cells in acute lung injury, and verify the protein expression of this molecule in tissues. Analyze the relationship between its phenotype and the degree of inflammation.
Study NCT05563467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG/ML [Keytruda]
Description: The treatment scheme will be based on pembrolizumab administered intravenously in cycles of every 3 weeks 200 mg, with supportive treatment with steroidogenesis inhibitor (metyrapone or ketoconazole) for adrenocortical carcinoma producing cortisol.
Study NCT05275790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestal device
Description: Battery powered non-invasive neurostimulation device
Study NCT05275790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: All subjects will be prescribed a diet plan and instructed to follow it for the duration of the 12-week study. The diet plan will be designed by the P.I. who is a qualified, obesity management coach.
Study NCT06401590 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FROZEN SENTINEL LYMPH NODE BIOPSY
Description: FROZEN SENTINEL LYMPH NODE BIOPSY
Study NCT05072002 — intervention group
Intervention type: OTHER
Intervention: no intervention / observational study
Description: no intervention / observational study
Study NCT05851157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.
Study NCT06111729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HabitAware group
Description: A device that provides gentle vibration when the motion of nail biting is sensed will be provided to all participants. Participants will use an app that connects to the device to track the frequency of their nail biting over the study period.
Study NCT05178563 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPT+PDT
Description: The experimental arm consist of performing IPT in randomly assigning patients to receive local use of photodynamic therapy (PDT).
Study NCT05178563 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: IPT+Placebo
Description: IPT+Placebo
Study NCT04669561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast 5% Ophthalmic Solution
Description: Open label, self-controlled, single group study of the efficacy of Lifitegrast 5% in improving higher order aberrations, ocular scatter index, and best corrected visual acuity in patients with dry eye. All patients will receive lifitegrast 5% for 4 weeks and will be evaluated at baseline (before treatment) and at 7, 14, and 28 days.
Study NCT06203925 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatitis C virus self-test (oral fluid HCVST)
Description: The participant will be able to choose between oral-fluid or blood-based HCVST. The package will include an HCV OraQuick ® HCV Self-Test kit, (OraSure Technologies, Inc, Bethlehem, PA) or a Wondfo® HCV Self-Test (Guangzhou, P.R. China) at Primary Study.~At Ancyllary study, the individuals attending PrEP consultations at INI/FIOCRUZ will be invited to perform HCVST using blood-based and oral-fluid kits.
Study NCT06203925 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatitis C virus self-test (blood-based HCVST)
Description: The participant will be able to choose between oral-fluid or blood-based HCVST. The package will include an HCV OraQuick ® HCV Self-Test kit, (OraSure Technologies, Inc, Bethlehem, PA) or a Wondfo® HCV Self-Test (Guangzhou, P.R. China) at Primary Study. At Ancylary Study, the individuals attending PrEP consultations at INI/FIOCRUZ will be invited to perform HCVST using blood-based and oral-fluid kits.
Study NCT05407311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-SAR-BBN
Description: 64Cu-SAR-BBN
Study NCT06551233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW2821
Description: Patients will be evaluated from low dose to high dose through intravesical therapy and then select the suitable doses to expand according to study data.
Study NCT05225779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 12- derivation Electrocardiography
Description: 6 precordial and 4 extremity electrodes will be placed at appropriate anatomical points and a total of 6 12-lead ECGs will be taken at different anesthesia depths before anesthesia induction and throughout the operation.
Study NCT05332821 — intervention group
Intervention type: DRUG
Intervention: PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
Description: PD-1/PD-L1 inhibitors: atezolizumab, sintilimab, pembrolizumab, nivolumab, camrelizumab, tislelizumab, toripalimab, durvalumab, penpulimab, and other ICIs; VEGF-TKI/bevacizumab: sorafenib, lenvatinib, donafenib, apatinib, anlotinib, bevacizumab/ bevacizumab biosimilar, and other anti-angiogenesis drugs; Both PD-1/PD-L1 inhibitors and anti-angiogenesis drugs only include marketed drugs but are not limited to HCC approval.
Study NCT05332821 — intervention group
Intervention type: PROCEDURE
Intervention: TACE
Description: TACE: cTACE (conventional TACE) or dTACE (drug-eluting beads TACE);
Study NCT05881525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TC-N201 cells
Description: T cells genetically engineered with a TCR targeting NY-ESO-1 (NY-ESO-1 TCR) that displays specific reactivity against HLA-A2+, NY-ESO-1+ target cells.
Study NCT05881525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Following cell infusion, the patient receives intravenous IL-2. IL-2 improves the survival of TC-N201 cells after infusion.
Study NCT05881525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Study NCT05881525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Study NCT05881525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Study NCT05170282 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Radiomic Algorithm
Description: Different radiomic, machine learning, and deep learning strategies for radiomic features extraction, sorting features and model constriction.
Study NCT06550765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodegradable Magnesium Metal Clips
Description: The tumor lesion area is exposed using conventional methods, and the tumor segment is resected according to the principles of tumor-free operation. Magnesium metal closure clips are used to clamp the tumor blood vessels, osteoperiosteal bleeding points, and other bleeding sites. The lesion area is thoroughly rinsed to ensure no active bleeding, and routine necessary reconstruction is performed.
Study NCT05734079 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: A written hand out containing all information required for bowel preparation
Study NCT05734079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care + Video call
Description: Standard of care and in addition a video call with a professional nurse conducted via digital devices and a free software (Zoom video communication or What's app application)
Study NCT05734079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care + Video call + Educational video film
Description: Standard of care and in addition to a video call, an explanatory short video on bowel preparation (video film), streamed to the patient's mobile device or computer
Study NCT05326477 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral weight loss treatment
Description: The weight loss intervention consists of the first 6 months of the Centers for Disease Control and Prevention's Prevent T2 program.
Study NCT04785781 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: without masks
Description: apply a bicycle ergometer test protocol to individuals without a mask
Study NCT04785781 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Surgical face mask (Vheal Med Co., Ltd., Istanbul, Turkey)
Description: apply a bicycle ergometer test protocol to individuals with a surgical mask
Study NCT04785781 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FFP2\N95 protective face mask (Musk protective technology, Gaziantep, Turkey)
Description: apply a bicycle ergometer test protocol to individuals with a FFP2\\N95 mask
Study NCT05569382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: 1. week: uptitration with 120 mg capsules per day, until maximum dosage of 360 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration
Study NCT05569382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: 1. week: uptitration with 2.5 mg capsules per day, until maximum dosage of 7.5 mg´s/day.~2-4. week: steady state treatment with the maximum tolerated dose.~5. week: downtitration